Compare ARK Innovation ETF (ARKK) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Innovation ETF vs TransMedics Group Inc — how do they compare? ARK Innovation ETF trades at $81, while TransMedics Group Inc trades at $87 (market cap $3.02B). The key difference: ARK Innovation ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| ARKK | TMDX | |
|---|---|---|
52-Week High | $92.50 | $150.42 |
52-Week Low | $63.52 | $61.99 |
Market Cap | — | $3.02B |
Sector | — | Technology |
Enterprise Value | — | $3.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARK Innovation ETF (ARKK) trades at $81.37, up 1.13% with a bullish technical signal from moving averages. The fund faces mixed sentiment with Seeking Alpha highlighting concentration risks and underperformance versus S&P 500, while Cathie Wood continues aggressive buying in AI stocks like CoreWeave. Technical indicators show overbought conditions with RSI at 91 on the 6-day timeframe.
Outlook remains challenged by high fees (0.75%), concentrated bets on Tesla and SpaceX, and limited AI exposure. The fund's venture-style approach creates volatility, with 37.88% losses over five years. Near-term performance hinges on Tesla's 10% weighting and AI stock momentum amid decelerating revenue growth in portfolio companies.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Innovation ETF
The fund will invest under normal circumstances primarily (at least 65% of its assets) in domestic and foreign equity securities of companies that are relevant to the fund’s investment theme of disruptive innovation. Its investments in foreign equity securities will be in both developed and emerging markets. The fund may invest in foreign securities listed on foreign exchanges as well as American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs). The fund is non-diversified.
Read more on ARKK →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
